Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(3):210-212
DOI: 10.5428/pcar20190313
Evaluation of inhaled long-acting anticholinergic drugs and long-acting β2 receptor agonists in the treatment of the patients with chronic obstructive pulmonary disease
1. XIA Yuandan1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China 564569218@qq.com)
2. 2(2.Department of Internal Medicine,Shanghai Jinshan Zhongren Aged Care Hospital,Shanghai 201501,China 564569218@qq.com)
3. DU Xiaomei1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China )
4. ZHOU Min1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China zhoumin-1209@163.com)
5. SHEN Meizhu1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China )
6. XU Li1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China )
7. TANG Hua1(1.Department of Respirtory Diseases,Jinshan Branch of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 201599,China )
ABSTRACT  Objective: To investigate the application value of inhaled long-acting anticholinergic drug (LAAD) and long-acting β2 receptor agonists(LABA) in the treatment of the patients designated as the B and C groups according to comprehensive evaluation of chronic obstructive pulmonary disease(COPD), in order to provide reference for the individualized treatment of COPD.Methods: Ninety-one patients designated as the B and C groups according to comprehensive evaluation of COPD were randomly divided into the LAAD group and the LABA group.The respiratory symptoms,COPD assessment test (CAT) scores,forced expiratory volume in one second (FEV1) and FEV1% pred were recorded at the time point of 0,2,4 and 6 months after treatment,and the efficacy,lung function improvement and safety were compared and evaluated between the two groups.Results: The CAT scores,FEV1 value and FEV1% pred of the patients in the two groups all improved,at the 4 and 6 months and the differences were statistically significant at the time point of the 6 month as compared with those of starting.The levels of FEV1 and FEV1% pred in the LAMA group were higher than those in the LABA group at the point of 6 month,and the difference was statistically significant.Conclusion: In the treatment of the stable patients in the B and C groups, both LAAD and LABA could improve clinical symptoms of COPD, and LAAD is superior to LABA in the improvement of pulmonary function.However, LAAD could induce dysuria in the course of medication, though the incidence of dysuria is relatively low, and attention should be paid to it.
Welcome to PCAR! You are the number 36 reader of this article!
Please cite this article as:
XIA Yuandan1,2,DU Xiaomei1,ZHOU Min1,SHEN Meizhu1,XU Li1,TANG Hua1,. Evaluation of inhaled long-acting anticholinergic drugs and long-acting β2 receptor agonists in the treatment of the patients with chronic obstructive pulmonary disease[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 210-212.
References:
1. Vogelmeier C F,Criner G J,Martinez F J,et al.Global strategy for the diagnosis,management and prevention of chronic obstructive lung disease 2017 report:GOLD executive summary[J].Respirology,2017,22(3):575-601.
2. Guirguis-Blake J M,Senger C A,Webber E M,et al.Screening for chronic obstructive pulmonary disease:evidence report and systematic review for the US preventive services task force[J].JAMA,2016,315(13):1378-1393.
3. Wise R A,Anzueto A,Cotton D,et al.Tiotropium respimat inhaler and the risk of death in COPD[J].N Engl J Med,2013,369(16):1491-1501.
4. Global Initiative for Asthma.2018 GINA Report,Global strategy for asthma management and prevention[EB/OL].[2018-06-30].(2018-10-24).http://ginasthma.org/gina-reports.
5. Latorre M,Novelli F,Vagaggini B,et al.Differences in the efficacy and safety among inhaled corticosteroids(ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD):role of ICS[J].Pulm Pharmacol Ther,2015,30:44-50.
6. Hizawa N.LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes[J].Int J Chron Obstruct Pulmon Dis,2015,10:1093-1102.
7. Singh D,Miravitlles M,Vogelmeier C.Chronic obstructive pulmonary disease individualized therapy:tailored approach to symptom management[J].Adv Ther,2017,34(2):281-299.
8. Chong J,Karner C,Poole P,et al.Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease[J].Cochrane Database Syst Rev,2012,12(9):CD009157.
9. Mahler D A,Kerstjens H A,Donohue J F,et al.Indacaterol vs tiotropium in COPD patients classified as GOLD A and B[J].Respir Med,2015,109(8):1031-1039.
10. ztürk C,Alda Y,Yilmaz Demirci N.Evaluation and importance of different types of inhaler device in patients with chronic obstructive lung disease[J].Tuberk Toraks,2017,65(2):69-79.
11. Yamada H,Hida N,Satoh H,et al.Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease[J].Chron Respir Dis,2018,15(4):419-420.
12. Chrystyn H,Small M,Milligan G,et al.Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD[J].Respir Med,2014,108(2):358-365.
13. Bogart M,Stanford R H,Reinsch T,et al.Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA:a retrospective study[J].Respir Med,2018,142:73-80.
14. Stephenson A,Seitz D,Bell C M,et al.Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease:a population-based study[J].Arch Intern Med,2011,171(10):914-920.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口